Sugi Predict

Sugi Predict / Compounds / SCHEMBL1806182

SCHEMBL1806182

SCHEMBL1806182

CCN1CCOCC1CN

nearest known ligand 0.37

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 4/20 0.37
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ GAA P10253 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890074 0.83 PDK1 (0.39) PDK1PDK2PDK3GAACA12
SCHEMBL25125561 0.83 PDK1 (0.39) PDK1PDK2PDK3GAACA12
SCHEMBL12621125 0.81 PDK1 (0.36) PDK1PDK2PDK3
SCHEMBL1700062 0.80 PDK1 (0.51) PDK1PDK2PDK3GAACA12
SCHEMBL17778486 0.80 PDK1 (0.51) PDK1PDK2PDK3GAACA12
SCHEMBL24630698 0.80 PDK1 (0.51) PDK1PDK2PDK3GAACA12
Hydrochloric Acid SCHEMBL31393754 0.80 PDK1 (0.37) PDK1PDK2PDK3CA12CA1
SCHEMBL28153082 0.79 PDK1 (0.37) PDK1PDK2PDK3
SCHEMBL21555136 0.78 PDK1 (0.34) PDK1PDK2PDK3
SCHEMBL23102877 0.77 PDK1 (0.36) PDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257064-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-08-14 — — US disclosed
US-12371431-B2 Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-07-29 — — US disclosed
CN-116199686-A Trifluoromethyl substituted sulfonamide compounds 正大天晴药业集团股份有限公司 2023-06-02 — — CN disclosed
CN-112888687-B Trifluoromethyl substituted sulfonamides selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2023-01-24 — — CN disclosed
US-20220220110-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-07-14 — — US disclosed
CN-114369094-A Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2022-04-19 — — CN disclosed
US-20220002290-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-01-06 — — US disclosed
US-20220002290-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-01-06 — — US disclosed
CN-111868059-B Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2021-12-03 — — CN disclosed
EP-3858832-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-08-04 — — EP disclosed
EP-3858832-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-08-04 — — EP disclosed
CN-112888687-A Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2021-06-01 — — CN disclosed
WO-2020238785-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR 正大天晴药业集团股份有限公司 2020-12-03 — — WO disclosed
CN-111868059-A Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors 正大天晴药业集团股份有限公司 2020-10-30 — — CN disclosed
WO-2019185025-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR 正大天晴药业集团股份有限公司 2019-10-03 — — WO disclosed
EP-2315767-B1 PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-09-04 — — EP disclosed
US-8436011-B2 Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-05-07 — — US disclosed
US-20110124643-A1 PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-05-26 — — US disclosed
EP-2315767-A2 PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2011-05-04 — — EP disclosed
WO-2010004197-A2 PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002290-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR BCL2L11, BCL2, BCL2L2 PDK1 1139/4885PDK2 1387/4885PDK3 2557/4885
US-20220220110-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR BCL2L11, BCL2, BCL2L1 PDK1 1208/4885PDK2 1628/4885PDK3 3034/4885
US-12371431-B2 Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor BCL2L11, BCL2, BCL2L2 PDK1 1139/4885PDK2 1387/4885PDK3 2557/4885
US-20110124643-A1 PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF FLT3, PDGFRB, PDGFRA PDK1 112/4885PDK2 154/4885PDK3 381/4885
US-20250257064-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR BCL2, BAX, BCL2L2 PDK1 1247/4885PDK2 1184/4885PDK3 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.